Compare GDC & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | TNXP |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 220.5M |
| IPO Year | N/A | 2008 |
| Metric | GDC | TNXP |
|---|---|---|
| Price | $3.81 | $13.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $70.00 |
| AVG Volume (30 Days) | 37.1K | ★ 285.9K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,094,000.00 |
| Revenue This Year | N/A | $7.00 |
| Revenue Next Year | N/A | $708.37 |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | ★ 29.94 |
| 52 Week Low | $1.76 | $12.35 |
| 52 Week High | $9.92 | $69.65 |
| Indicator | GDC | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 36.55 |
| Support Level | $3.09 | N/A |
| Resistance Level | $4.41 | $20.36 |
| Average True Range (ATR) | 0.42 | 0.68 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 64.52 | 25.41 |
GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.